The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.

Some of the key findings include:

  • Venture Capital: A decade high in 2014 for US venture capital in Novel R&D lead programs. However, Series A investments went to fewer companies and with fewer dollars vs 2013. Additionally, some disease areas affecting large populations continue to see declines.
  • IPOs: A decade high in 2014 for U.S. emerging company IPOs.
  • Follow-On Offerings: A decade high in 2014 for U.S. emerging company follow-on offerings.
  • Licensing: A decade high in 2014 for upfront payments in R&D-stage licensing deals.
  • Acquisitions: R&D-stage acquisition volume is returning to levels not seen since 2008.
  • Pipeline: Nearly 70% of the industry clinical pipeline is attributed to small emerging companies. A significant portion of the emerging company pipeline (43%) is partnered.

Furthermore, the report provides a more in-depth look at the major disease categories for drug R&D. This section showcases recent interest levels across the five investment and deal making activities with respect to each therapeutic area.

The podcast can be accessed here:

The free report – Emerging Therapeutic Company Investment and Deal Trends – can be accessed here. For more information on BIO Industry Analysis, please visit http://www.biotech-now.org/business-and-investments/inside-bio-ia.

 

 

Filed under: Business and Investments, Inside BIO Industry Analysis, , , , , ,